• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,139
109
75
71
68

COUNTRY

70
22
16
10
9

CATEGORIES

  • 574
  • 118
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

879
1,165
1,601
2,946

PUBLISHED

152
240
686
2,946

PRODUCT TYPE

2,375
494
67
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

Metastatic Prostate Cancer - Pipeline Review, H2 2013

Metastatic Prostate Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

August 2013
FROM

Prostate Cancer - Pipeline Review, H2 2013

Prostate Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

August 2013
FROM

Cervical Cancer - Pipeline Review, H2 2013

Cervical Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

August 2013
FROM

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2013

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder...

August 2013
FROM

Bladder Cancer - Pipeline Review, H2 2013

Bladder Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

August 2013
FROM

Lung Adenocarcinoma - Pipeline Review, H2 2013

Lung Adenocarcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lung Adenocarcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

August 2013
FROM

Anaplastic Thyroid Cancer - Pipeline Review, H2 2013

Anaplastic Thyroid Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Anaplastic Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

August 2013
FROM

Bone Metastasis - Pipeline Review, H2 2013

Bone Metastasis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Bone Metastasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

August 2013
FROM

Lymphoma - Pipeline Review, H2 2013

Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

August 2013
FROM

Non-Hodgkin Lymphoma - Pipeline Review, H2 2013

Non-Hodgkin Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Non-Hodgkin Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

August 2013
FROM

Melanoma - Pipeline Review, H2 2013

Melanoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

August 2013
FROM
Disease and Therapy Review: Ovarian Cancer Disease and Therapy Review: Ovarian Cancer - Product Thumbnail Image

Disease and Therapy Review: Ovarian Cancer

The Ovarian Cancer Disease and Therapy Review provides an overview of ovarian cancerm, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, as well as information...

August 2013
FROM
Disease and Therapy Review: Ovarian Cancer Disease and Therapy Review: Ovarian Cancer - Product Thumbnail Image

Disease and Therapy Review: Ovarian Cancer

The Ovarian Cancer Disease and Therapy Review provides an overview of ovarian cancerm, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, as well as information...

August 2013
FROM
Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors - Product Thumbnail Image

Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors

Product description The present Competitive Intelligence report about Bruton’s Tyrosine Kinase (BTK) Inhibitorsprovides a competitor evaluation in the field of small molecule-based inhibitors of Bruton’s...

August 2013
FROM

OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017 Summary Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a...

August 2013
FROM
Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitors Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitors - Product Thumbnail Image

Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitors

The present Competitive Intelligence report about Focal Adhesion Kinase (FAK) Inhibitors provides a competitor evaluation in the field of small molecule-based inhibitors of Focal Adhesion Kinase (FAK)...

August 2013
FROM

Global Stem Cell Anticancer Therapeutics Market 2012-2016

The analysts forecast the Global Stem Anticancer Therapeutics market to grow at a CAGR of 11 48 percent over the period 2012-2016 Increasing investment in R&D is one of the key factors contributing...

August 2013
FROM
Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors - Product Thumbnail Image

Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors

Product description The present Competitive Intelligence report about Anaplastic Lymphoma Kinase (ALK) Inhibitors provides a competitor evaluation in the field of small molecule and antibody-based inhibitors...

August 2013
FROM
Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside - Product Thumbnail Image

Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside

Protein kinases are key regulators of cell function that constitute one of the largest and most functionally diverse gene families with approximately 518 kinases encoded by the human genome. They direct...

August 2013

Pancreatic Cancer Drug Pipeline Analysis

"“Pancreatic Cancer Drug Pipeline Analysis” gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer This research report covers all the ongoing...

August 2013
FROM
Loading Indicator

Our Clients

Our clients' logos